Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging...
share announcement

Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging In Vitro Approaches

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 11134

Special Issue Editor

Dr. Silvia Scaglione

E-Mail Website
Guest Editor
1. React4life SRL, 16121 Genova, Italy
2. National Research Council of Italy, Institute of Electronics, Information Engineering and Telecommunications (IEIIT), 16149 Genova, Italy
Interests: 3D tumor models; organ on chip; cells migration; drug efficacy; 3R in vitro approaches; immunooncology

Special Issue Information

Dear Colleagues,

In recent years, cancer immunotherapy has emerged as a promising therapeutic strategy to improve the treatment and benefits of individual patients. However, mechanisms behind tumor immunogenicity, immune cell invasion, adaptive immune responses against cancer, and escape mechanisms are still not completely elucidated.

In this context, the availability of more reliable preclinical models capable of recapitulating the real complexity of the human tumor microenvironment while overcoming the limitations of traditional approaches becomes mandatory. In particular, it is important to find ways to evolve current in vitro/in vivo models to become more predictive of the human patient heterogeneity and response to testing therapies.

This Special Issue will focus on translational research aimed at discussing the main challenges and possible future trends of cancer immunotherapies, by deepening novel and emerging in vitro approaches, such as immune component 3D tumor models, organ-on-chip technologies, tumor organoids, and 3D bioprinting.

Dr. Silvia Scaglione
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune-oncology
  • 3D tumor models
  • immune-tumor crosstalk
  • immune cells infiltration
  • immune-modulating agents
  • immune-organ on chip
  • spheroids
  • cell therapies

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

15 pages, 1340 KiB  
Review
Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by Pengbo Yang and Junhua Zhang
Biomedicines 2023, 11(7), 1988; https://doi.org/10.3390/biomedicines11071988 - 13 Jul 2023
Cited by 1 | Viewed by 1879
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme involved in catalyzing the conversion of tryptophan (Trp) into kynurenine (Kyn) at the first rate-limiting step in the kynurenine pathway of L-tryptophan metabolism. It has been found to be involved in several biological functions such [...] Read more.
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme involved in catalyzing the conversion of tryptophan (Trp) into kynurenine (Kyn) at the first rate-limiting step in the kynurenine pathway of L-tryptophan metabolism. It has been found to be involved in several biological functions such as aging, immune microorganism, neurodegenerative and infectious diseases, and cancer. IDO1 plays an important role in immune tolerance by depleting tryptophan in the tumor microenvironment and inhibiting the proliferation of effector T cells, which makes it an important emerging biomarker for cancer immunotherapy. Therefore, the research and development of IDO1 inhibitors are of great importance for tumor therapy. Of interest, IDO activity assays are of great value in the screening and evaluation of inhibitors. Herein, we mainly review the biological functions of IDO1, immune regulation, key signaling molecules in the response pathway, and the development of IDO1 inhibitors in clinical trials. Furthermore, this review provides a comprehensive overview and, in particular, a discussion of currently available IDO activity assays for use in the evaluation of IDO inhibitors in human blood. We believe that the IDO activity is a promising biomarker for the immune escape and laboratory evaluation of tumor immunotherapy. Full article
(This article belongs to the Special Issue Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging In Vitro Approaches)
►▼ Show Figures

Figure 1

13 pages, 3068 KiB  
Review
Updates on Lymphovascular Invasion in Breast Cancer
by Elisabetta Kuhn, Donatella Gambini, Luca Despini, Dario Asnaghi, Letterio Runza and Stefano Ferrero
Biomedicines 2023, 11(3), 968; https://doi.org/10.3390/biomedicines11030968 - 21 Mar 2023
Cited by 9 | Viewed by 7748
Abstract
Traditionally, lymphovascular invasion (LVI) has represented one of the foremost pathological features of malignancy and has been associated with a worse prognosis in different cancers, including breast carcinoma. According to the most updated reporting protocols, the assessment of LVI is required in the [...] Read more.
Traditionally, lymphovascular invasion (LVI) has represented one of the foremost pathological features of malignancy and has been associated with a worse prognosis in different cancers, including breast carcinoma. According to the most updated reporting protocols, the assessment of LVI is required in the pathology report of breast cancer surgical specimens. Importantly, strict histological criteria should be followed for LVI assessment, which nevertheless is encumbered by inconsistency in interpretation among pathologists, leading to significant interobserver variability and scarce reproducibility. Current guidelines for breast cancer indicate biological factors as the main determinants of oncological and radiation therapy, together with TNM staging and age. In clinical practice, the widespread use of genomic assays as a decision-making tool for hormone receptor-positive, HER2-negative breast cancer and the subsequent availability of a reliable prognostic predictor have likely scaled back interest in LVI’s predictive value. However, in selected cases, the presence of LVI impacts adjuvant therapy. This review summarizes current knowledge on LVI in breast cancer with regard to definition, histopathological assessment, its biological understanding, clinicopathological association, and therapeutic implications. Full article
(This article belongs to the Special Issue Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging In Vitro Approaches)
►▼ Show Figures

Figure 1

Other

Jump to: Review

14 pages, 638 KiB  
Study Protocol
The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
by Ana Erman, Marija Ignjatović, Katja Leskovšek, Simona Miceska, Urša Lampreht Tratar, Maša Bošnjak, Veronika Kloboves Prevodnik, Maja Čemažar, Lidija Kandolf Sekulovič, Gorazd Avguštin, Janja Ocvirk and Tanja Mesti
Biomedicines 2023, 11(7), 2016; https://doi.org/10.3390/biomedicines11072016 - 18 Jul 2023
Cited by 1 | Viewed by 1087
Abstract
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression of PD-L1 and IFNγ [...] Read more.
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression of PD-L1 and IFNγ from the primary tumor, stool and body fluids as potential biomarkers for response. Methods: Patients treated with immune checkpoint inhibitors as a first line treatment for metastatic melanoma are recruted to this prospective study. Stool samples are submitted before the start of treatment, at the 12th (+/−2) week and 28th (+/−2) week, and at the occurrence of event (suspected disease progression/hyperprogression, immune-related adverse event (irAE), deterioration). Peripheral venous blood samples are taken additionally at the same time points for cytologic and molecular tests. Histological material from the tumor tissue is obtained before the start of immunotherapy treatment. Primary objectives are to determine whether the human gastrointestinal microbiome (bacterial and viral) and the exosomal mRNA expression of PD-L1 and IFNγ and its dynamics predicts the response to treatment with PD-1 and CTLA-4 inhibitors and its association with the occurrence of irAE. The response is evaluated radiologically with imaging methods in accordance with the irRECIST criteria. Conclusions: This is the first study to combine and investigate multiple potential predictive and prognostic biomarkers and their dynamics in first line ICI in metastatic melanoma patients. Full article
(This article belongs to the Special Issue Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging In Vitro Approaches)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop